APAndré Pannatier

André Pannatier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


André Pannatier has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine

    by Myriam Arevalo-Herrera, Michelle Larmart-Delgado, Maria Alejandra Caicedo, Juliana Henao-Geraldo, Angelica Castellanos, Xiomara Gaitan, Jean-Christophe Devaud, André Pannatier, Sonia Herrera, Jose Oñate, et al.

    A randomized, double-blind, controlled clinical trial was conducted to assess the safety and protective efficacy of the Plasmodium vivax circumsporozoite (CS) protein. A total of 35 healthy adults, either malaria-naïve (n = 17) or P.vivax semi-immune (n = 18), were enrolled and immunized intramuscularly (i.m.) at months 0, 2, and 6, with the PvCS (150 µg) formulated in Montanide ISA-51 adjuvant. Most volunteers developed PvCS specific antibody and T-cell responses and were subjected to a P. vivax sporozoite controlled human malaria infection (CHMI) 30 days after the last immunization. Sterile protection was observed in five of 11 naïve (42%) and four of 11 semi-immune (36%) volunteers by showing no parasitemia during the 60 days follow-up, as did a semi-immune control (1/5) volunteer. All non-protected volunteers developed malaria symptoms 10–19 days after CHMI and were immediately treated with antimalarial drugs. This is the first study of a P. vivax sub-unit vaccine demonstrating sterile protection against P. vivax infection.

  • Description and analysis of hospital pharmacies in Madagascar

    by H.R. Ratsimbazafimahefa, F. Sadeghipour, P. Trouiller, A. Pannatier, B. Allenet


  • A bundle with a preformatted medical order sheet and an introductory course to reduce prescription errors in neonates

    by David Palmero, Ermindo R. Di Paolo, Lydie Beauport, André Pannatier, Jean-François Tolsa

    The objective of this study was to assess whether the introduction of a new preformatted medical order sheet coupled with an introductory course affected prescription quality and the frequency of errors during the prescription stage in a neonatal intensive care unit (NICU). Two-phase observational study consisting of two consecutive 4-month phases: pre-intervention (phase 0) and post-intervention (phase I) conducted in an 11-bed NICU in a Swiss university hospital. Interventions consisted of the introduction of a new preformatted medical order sheet with explicit information supplied, coupled with a staff introductory course on appropriate prescription and medication errors. The main outcomes measured were formal aspects of prescription and frequency and nature of prescription errors. Eighty-three and 81 patients were included in phase 0 and phase I, respectively. A total of 505 handwritten prescriptions in phase 0 and 525 in phase I were analysed. The rate of prescription errors decreased significantly from 28.9 % in phase 0 to 13.5 % in phase I (p < 0.05). Compared with phase 0, dose errors, name confusion and errors in frequency and rate of drug administration decreased in phase I, from 5.4 to 2.7 % (p < 0.05), 5.9 to 0.2 % (p < 0.05), 3.6 to 0.2 % (p < 0.05), and 4.7 to 2.1 % (p < 0.05), respectively. The rate of incomplete and ambiguous prescriptions decreased from 44.2 to 25.7 and 8.5 to 3.2 % (p < 0.05), respectively. Conclusion: Inexpensive and simple interventions can improve the intelligibility of prescriptions and reduce medication errors. What is Known: • Medication errors are frequent in NICUs and prescription is one of the most critical steps. • CPOE reduce prescription errors, but their implementation is not available everywhere. What is New: • Preformatted medical order sheet coupled with an introductory course decrease medication errors in a NICU. • Preformatted medical order sheet is an inexpensive and readily implemented alternative to CPOE. What is Known: • Medication errors are frequent in NICUs and prescription is one of the most critical steps. • CPOE reduce prescription errors, but their implementation is not available everywhere. What is New: • Preformatted medical order sheet coupled with an introductory course decrease medication errors in a NICU. • Preformatted medical order sheet is an inexpensive and readily implemented alternative to CPOE.


  • Open Access

    The Hospital Pharmacist: An Important Contributor to Improved Patient Safety in the Hospital

    by Stéphanie Berthouzoz, Lina Berger, Pascal Bonnabry, André Pannatier

    Injectable drugs are high-risk products and their reconstitution in hospital wards is a potential source of errors. Thus, in order to secure the reconstitution process and thereby improve safety, the pharmacy department of Lausanne University Hospital is focusing on developing ready-to-use forms (CIVAS). These preparations are compounded in controlled clean rooms and are analyzed prior to release. In the intensive care unit, amiodarone 12.5 mg/mL in glucose 5% is one of the high-risk preparations, which has led the pharmacy to develop a ready-to-use solution. To this end, a one-year stability study was initiated, and the preliminary results (after six months) are illustrated here. A stability-indicating HPLC method was developed and validated for monitoring the concentration of amiodarone. Batches were stored at 5 °C and 30 °C, which were analyzed immediately after preparation, after one, two, four and six months of storage. The pH and osmolality values were monitored at the respective time intervals. It was observed that after six months, all the results were within specifications. However, the pH values started to decrease after two months when amiodarone was stored at 30 °C. After six months, a degradation peak appeared on the chromatogram of these solutions, which suggested that amiodarone is more stable at 5 °C. The preliminary results obtained in this study indicated that injectable amiodarone solutions are stable for six months under refrigerated storage conditions. The study is ongoing.


  • The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube

    by Gregory Podilsky, Markoulina Berger-Gryllaki, Bernard Testa, Thierry Buclin, Michel Roulet, Andre Pannatier

    To characterize and compare the pharmacokinetic profiles of bromazepam, omeprazole and paracetamol when administered by the oral and nasogastric routes to the same healthy cohort of volunteers. In a prospective, monocentric, randomized crossover study, eight healthy volunteers received the three drugs by the oral (OR) and nasogastric routes (NT). Sequential plasma samples were analyzed by high-performance liquid chromatography–UV, pharmacokinetic parameters (Cmax, \({\text{AUC}}_{0 - \infty } \) , t½, ke, tmax) were compared statistically, and Cmax, \({\text{AUC}}_{0 - \infty } \) and tmax were analyzed for bioequivalence. A statistically significant difference was seen in the \({\text{AUC}}_{0 - \infty } \) of bromazepam, with nasogastric administration decreasing availability by about 25%: AUCOR = 2501 ng mL−1 h; AUCNT = 1855 ng mL−1 h (p < 0.05); ratio (geometric mean) = 0.74 [90% confidence interval (CI) 0.64–0.87]. However, this does not appear to be clinically relevant given the usual dosage range and the drug’s half-life (approx. 30 h). A large interindividual variability in omeprazole parameters prevented any statistical conclusion from being drawn in terms of both modes of administration despite their similar average profile: AUCOR = 579 ng mL−1 h; AUCNT = 587 ng mL−1 h (p > 0.05); ratio (geometric mean) = 1.01 (90% CI 0.64–1.61). An extended study with a larger number of subjects may possibly provide clearer answers. The narrow 90% confidence limits of paracetamol indicate bioequivalence: AUCOR = 37 μg mL−1 h; AUCNT = 41 μg mL−1 h(p > 0.05); ratio (geometric mean) = 1.12 (90% CI 0.98–1.28). The results of this study show that the nasogastric route of administration does not appear to cause marked, clinically unsuitable alterations in the bioavailability of the tested drugs.


  • Open Access

    Formulation Optimization in a University Hospital: The Example of Pediatric Solutions of the ACE Inhibitor Captopril

    by Markoulina Berger-Gryllaki, Grégory Podilsky, Nicolas Widmer, Stéphane Gloor, Bernard Testa, André Pannatier

    Many major drugs are not available in pediatric form. As a result, hospital pharmacists are often requested to provide the medical staff with liquid formulations for individualized dosage and easy administration to newborn and young patients. Such in-house formulations must of course fulfil stringent criteria of purity and stability. This paper reports the development of a liquid solution of captopril for pediatric use. A specific HPLC-UV method was developed. A number of formulations described in the literature as affording one-month stability were examined and found wanting. A simple solution of the drug (1 mg/ml) in purified water containing 0.1% EDTA-Na proved chemically and microbiologically stable at room temperature for two years.